Recursion reported two confirmed responses in endometrial cancer and a 91.7% disease-control rate at doses of 45 mg or higher; Sanofi optioned a candidate.

At the dawn of the era where AI improves AI, I will write about what I, as someone in the field, have been thinking.ELYZA ...

Recursion Pharmaceuticals Inc. stocks have been trading down by -10.42 percent after bearish sentiment over slowing pipeline progress. Key Takeaways RXRX is pulling back after a failed push above $5, ...

Recursion Pharmaceuticals Inc. stocks have been trading down by -4.43 percent after AI drug-discovery partnership concerns ...

MIT’s Alex Zhang reveals why OpenAI and Anthropic coding agents are basically the same, sparking debate in AI development ...

Right now, leading artificial intelligence models need human supervision to improve—but a popular theory known as "recursive ...

"AI will start creating smarter AI on its own."Hearing that might sound a bit like science fiction.But right now, the concept ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.70, marking a -1.2% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.77%. On ...

What happens when artificial intelligence systems start to think for themselves, make themselves more powerful and escape human control in their quest to achieve superintelligence? That prospect has ...

There Is Something We Have to Do Right Now About A.I. Artificial intelligence labs are on the verge of handing over the training of A.I. to A.I. We should stop them. There’s a chasm right now between ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. Dario Amodei, CEO and co-founder of Anthropic ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Anthropic co-founder Dario Amodei urges a deliberate slowdown in AI development, emphasizing ...